The successful usage of BH3 mimetics to reduce chemoresistance in multiple cancer types, along with the knowledge that Bcl-2 and/or Bcl-xL are overexpressed in many MI-BC patients, indicate that the concurrent treatment of BH3 mimetics with cisplatin could improve MI-BC patients’ response rate to NAC. The gene discussed is BCL2; the disease is breast cancer.